In a recent announcement, Beam Therapeutics Inc. revealed that Eli Lilly and Company (Lilly) will acquire certain rights from Beam’s collaboration and license agreement with Verve Therapeutics, Inc. This agreement includes Beam’s opt-in rights to co-develop and co-commercialize Verve’s base editing programs for cardiovascular disease, targeting PCSK9, ANGPTL3, and an undisclosed liver-mediated, cardiovascular target.
Under the terms of the agreement, Beam will receive an upfront payment of $200 million and a $50 million equity investment from Lilly. Additionally, Beam is eligible for up to $350 million in potential future development-stage payments, contingent on the completion of specific clinical, regulatory, and alliance milestones, resulting in a potential total deal consideration of up to $600 million.
Beam Therapeutics, a biotechnology company specializing in precision genetic medicines through base editing, views this collaboration as an opportunity to expand its portfolio of clinical and research-stage programs. Base editing is a proprietary technology that enables precise, predictable, and efficient single base changes in targeted genomic sequences, offering a potential therapeutic strategy for various diseases.
Lilly’s interest in this partnership is driven by the potential of single-course gene editing treatments for patients at risk of cardiovascular disease. The collaboration seeks to harness the full potential of Beam’s base editing platform and Verve’s cardiovascular disease programs to develop innovative therapeutic options.
This collaboration reflects Beam’s commitment to advancing genetic medicine and its goal of providing lifelong cures for serious diseases. However, investors should exercise caution, as the success of these endeavors depends on various factors, including regulatory approvals, clinical trial outcomes, and the availability of funding. Beam will continue to pursue its mission while closely monitoring potential risks and uncertainties associated with these developments.
https://www.fiercebiotech.com/biotech/beam-offloads-verve-rights-lilly-600m-and-more-deals-are-works
https://www.globenewswire.com/news-release/2023/10/31/2769940/0/en/Beam-Announces-Agreement-for-Lilly-to-Acquire-Beam-s-Opt-In-Rights-to-Verve-Therapeutics-Base-Editing-Programs-for-Cardiovascular-Disease.html
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Neurona Secures $102M to Advance Epilepsy Cell Therapy to Phase 3
Neurona Therapeutics has secured $102 million to fund its Phase 3 trial of NRTX-1001, an off-the-shelf cell therapy for epilepsy. The oversubscribed financing round, supported by over 15 investors including Fidelity Management & Research Company, the Column Group,...
European Medicines Agency Requests Pause on Trials for Sarepta’s DMD Gene Therapy
Sarepta and Roche have temporarily halted three European clinical trials of their DMD gene therapy Elevidys, following an EMA request after a 16-year-old patient death in the U.S. The paused trials, including studies in boys and newborns, are on hold pending analysis...
Capsida’s CAP-003 Shows Promise in NHP Study for GBA-Parkinson’s Disease
THOUSAND OAKS, Calif., April 3, 2025 – Capsida Biotherapeutics (“Capsida”) announced new data from a three-month GLP toxicology study in non-human primates (NHPs) with CAP-003, its intravenously (IV) delivered gene therapy for Parkinson’s disease associated with GBA...
EMA Provides Positive Feedback on Variant’s VAR002 Development Pathway
PARIS, April 3, 2025 /PRNewswire/ Variant and the Rare Ocular Diseases Center at the University of Campania Luigi Vanvitelli (UCLV) today announced positive feedback from the EMA on VAR002, an AAV gene therapy for inherited retinal dystrophies linked to CRX...
Related Services
